ADHD drug trial for preschoolers pulled before it started
NCT ID NCT07169162
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test whether ADZENYS XR-ODT, a once-daily amphetamine tablet that dissolves in the mouth, could help manage ADHD symptoms in children aged 4 to less than 6 years. The trial was planned as a randomized, double-blind, placebo-controlled study, but it was withdrawn before enrolling any participants. As a result, no data or conclusions are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ADZENYS XR-ODT (amphetamine, an extended-release tablet that dissolves in the mouth)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Expected to start
-
May 2019
An estimate. Start dates often move.
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
4 to 5 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subject meets DSM-5 criteria for ADHD, combined, hyperactive/impulsive, or inattentive presentation made during a clinical interview by an experienced clinician and confirmed with the K-SADS-PL. * Subject has an age- and sex-adjusted rating of ≥90th percentile Total Score on the ADHD RS-IV Preschool Version (rated over past 6 months). * Subject has a score of ≥4 on the CGI-S at Visit 2 (Baseline). * Subject has had symptoms consistent with ADHD for at least 6 months. * Subject has a Peabody Picture Vocabulary Test, 4th edition Standard Score of ≥70 at Visit 1 (Screening Visit). * Subject has undergone an adequate course of nonpharmacological treatment for ADHD based on investigator judgment or the investigator considers the subject's condition severe enough to enroll without undergoing prior nonpharmacological treatment. Subjects who have been on a previous pharmacological treatment for ADHD may be enrolled provided they meet other entrance criteria. * Subject has participated in structured group activity (e.g., preschool, daycare, camp) for at least 1 month that in the investigator's opinion allows assessment of symptoms and impairment in a setting outside of the home. Exclusion Criteria: * Other psychiatric diagnoses * Significant cognitive impairment * Chronic medical illnesses * Structural cardiac defects * Significant abnormal lab tests * Taking disallowed medications * Subject has history of or presence at Screening of long QT syndrome or QTc greater than 450 msec at Screening (using Fridericia's formula: QTcF) or any other clinically significant 12-lead ECG abnormality. * Subject has a history of chronic vocal or motor tics or Tourette's syndrome or a family history of Tourette's syndrome. * Subject has history or presence of suicidal ideation, significant self-injurious behavior, or violent behavior. * Subject shows evidence of current physical, sexual, or emotional abuse. * Subject has a height or a weight less than or equal to the 5th percentile for age and sex at the Screening Visit. * Subject's blood pressure measurements exceed the 95th percentile for age, sex, and height at the Screening Visits (Visit 1) and/or Baseline Visit (Visit 2) per the American Academy of Pediatrics 2017 updated guidance. * Subject's biological parent has a history of bipolar disorder. * A parent/caregiver or someone living in the subject's home has a current or recent (past 12 months) history of substance abuse.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Attention deficit hyperactivity disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Psychiatry and Behavioral Medicine, Inc.
Las Vegas, Nevada, 89128, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI chatbot app aims to ease parental stress
- Could hidden ADHD symptoms be dragging down medical Students' grades?
- Can virtual worlds teach Real-Life social skills to kids with ADHD?
- Disaster-Proofing ADHD: a parent training program to the test
- Can tailored school support boost behavior and language in kids with ADHD?
- Could a gentle massage at bedtime help kids with ADHD sleep?